Insmed (INSM) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Insmed (NASDAQ: INSM):

• 8/10/2026 – Insmed had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $195.00 price target on the stock, up from $185.00.
• 8/10/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright.
• 8/10/2026 – Insmed had its price target lowered by JPMorgan Chase & Co. from $179.00 to $175.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Insmed had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $218.00 price target on the stock.
• 8/7/2026 – Insmed had its “outperform” rating reaffirmed by Evercore Inc. They now have a $170.00 price target on the stock.
• 8/7/2026 – Insmed had its price target lowered by Guggenheim from $207.00 to $205.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Insmed had its “buy” rating reaffirmed by UBS Group AG. They now have a $172.00 price target on the stock.
• 8/7/2026 – Insmed had its price target raised by Wells Fargo & Company from $161.00 to $169.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Insmed had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $175.00 price target on the stock.
• 7/28/2026 – Insmed had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $235.00 price target on the stock.
• 7/20/2026 – Insmed is now covered by BMO Capital Markets. They set an “outperform” rating and a $192.00 price target on the stock.
• 7/20/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright. They now have a $220.00 price target on the stock.
• 7/20/2026 – Insmed was upgraded by BMO Capital Markets to “strong-buy”.
• 7/17/2026 – Insmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Insmed had its price target raised by Wells Fargo & Company from $160.00 to $161.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Insmed had its “buy” rating reaffirmed by Guggenheim. They now have a $207.00 price target on the stock.

Insider Buying and Selling at Insmed

In other news, COO Roger Adsett sold 239,850 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares in the company, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the transaction, the chief executive officer directly owned 259,058 shares of the company’s stock, valued at approximately $30,413,409.20. This trade represents a 3.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 288,291 shares of company stock worth $37,091,566 over the last ninety days. 2.10% of the stock is currently owned by company insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.